Flagship Pioneering commits £100 million to establish an AI-native biotech venture creation unit in London

Flagship Pioneering, the US life sciences venture creation firm behind companies including Moderna, has committed an initial £100 million to establish the Flagship Origination Lab, U.K., its first dedicated company-creation unit outside the United States. Based in London, the new operation will develop AI-native platform companies, building on Flagship’s experience of originating more than 130 companies.

A new model for biotech company creation

The new laboratory will operate as part of Flagship Labs, the company’s innovation foundry. Its remit will cover the conception, testing, funding and development of AI-native platform companies focused on human and planetary health, as well as other areas of science and technology.

Rather than concentrating on investments in existing businesses, Flagship intends to apply its established company-origination model, developing new ventures from scientific concepts and building them into independent companies.

The firm expects to recruit and train an initial team of approximately 50 scientist-entrepreneurs and operators in the United Kingdom.

The London initiative represents the first international expansion of Flagship’s company-creation model, which the company has developed in Cambridge, Massachusetts, over more than 25 years. Its portfolio includes Moderna and Generate:Biomedicines, among other biotechnology companies.

£100 million initial commitment and a further £500 million partnership target

Flagship has allocated an initial £100 million to establish and develop the new operation. According to founder and CEO Noubar Afeyan, the company anticipates scaling this commitment by attracting an additional £500 million through partnerships.

The proposed partnerships are expected to involve British universities, corporations and other potential funders. The additional funding is a target rather than capital already secured.

The initiative builds on three years of activity in the United Kingdom. Flagship opened its London office in 2023 and signed a memorandum of understanding with the UK Government to expand the international reach of its portfolio companies.

During this period, the company launched Quotient Therapeutics, its first transatlantic venture.

NHS data and the UK’s research infrastructure

Access to the UK’s scientific and clinical infrastructure was an important factor in Flagship’s decision to establish the new unit in London.

Afeyan identified the National Health Service (NHS) and its extensive patient data resources as a particularly significant attraction. These datasets could support the use of real-world evidence to identify and investigate disease targets before researchers proceed to designing new therapeutic candidates. However, the announcement does not identify any specific NHS data-access agreements for the new laboratory.

The company also cited the UK’s strengths in genomics, clinical-trial infrastructure, academic research and regulatory innovation.

A Flagship-founded company has already established a clinical research presence in the country. Generate:Biomedicines completed an early-stage clinical trial in Manchester involving an AI-designed candidate for asthma.

AI as a foundation for scientific innovation

Artificial intelligence is expected to be integrated throughout the new laboratory’s company-creation activities, from scientific hypothesis generation and target identification to molecular design and clinical development.

However, Afeyan cautioned that the use of AI in drug development is still at an early stage. In his assessment, one of its most important early contributions will be improving the understanding of disease biology and the mechanisms underlying pathological processes.

“We’re in an age where I think AI’s most fundamental contribtion in the first instance will be to shed a light on actually what’s happening mechanistically in diseases,” Afeyan told Reuters.

The approach reflects Flagship’s broader strategy of combining scientific research, computational capabilities and venture creation to develop new technology platforms.

UK government welcomes the investment

Chris McDonald MP, the UK’s Minister of State for Science, Innovation and Investment, welcomed Flagship’s decision to establish the new operation in London.

He said the investment would help translate UK research strengths in artificial intelligence and life sciences into new businesses, jobs and economic growth.

The Flagship Origination Lab is intended to connect UK-based scientific talent and research institutions with the company’s international venture-building infrastructure.

POPULAR